THREE REASONS TO INVEST

Positioned as an ideal pain-free medication delivery device due to its low cost to produce and its rapid, safe, painless and efficient delivery of the drug.

 

Nothing comparable on the market. PKA Micro-Needle addresses the needs of healthcare workers and patients.

Injectable drugs are central to the global pharmaceutical industry, with a projected value of more than US 1 trillion dollars by 2027 with the medical technology industry projected to cross revenue of almost US 797 billion dollars by 2025, growing at a Compound Annual Growth Rate (CAGR) of 5.6 from 2020 to 2025.

ONE STEP AWAY FROM COMMERCIALIZATION

Notably, we are well on our way through the drug approval pathway process.

We have refined our technology and our Generation VI Micro-Needle, our final and perfected device, was finalized in 2018. It has passed all testing with 100 per cent reliability. We now must confirm efficacy and safety in order to receive regulatory approvals and be available for potential drug company licences. Our next step is to complete veterinary clinical trials, which shall be conducted in 2022 at the University of Guelph, Ontario. 

We are now raising a fourth round of capital to perform human clinical trials and secure licenses with pharmaceutical companies who will then manufacture and sell our device in the human medical market.  By investing, you will receive shares and become a co-owner of PKA SoftTouch, and have the potential to profit from the sale of each and every device. 

Clinical Trials

Proof of Concept clinical trials completed & data generated.

PHASE I: Animal Trial
PHASE II: Human Trial

 

License with Pharmaceutical Company

Pharmaceutical company receive clinical trial data then fill device with drug they produce.

Drug Company
(Distributes Micro-
Needle to market)

Large-scale licensee manufacturers, prefills & sells device.

PKA manufactures & pre-fills device & small-scale licensee sells

Revenue

Royalties from each sale.

Manufacturing Profit & Royalties from each sale.

SCIENTIFIC PAPERS

The following article was written by two of PKA SoftTouch’s founders: Dr. Pankaj Modi and Maneesh Khanna – together with Marko Mihic.

The article provides information on early testing and results of the Micro-Needle.

 

Advanced Devices Article

Veterinary Pharmacology and Therapeutics

Micro-Injection Atropine Study

GLOBAL PATENTS

A key component for financial success and stability is the protection of our technology. Patentability also plays a vital role in a medical device company’s shareholder value.

We have protected our intellectual property in 23 countries: Canada, United States, India, Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Spain, Sweden, Switzerland, United Kingdom, Japan, New Zealand, South Africa, Brazil and Australia. Patents are still pending in Argentina.

Applied for US PCT in 2019, to update recent improvements in our device technology. Presently, PKA is perfecting in some countries that we are protected in with initial patents. More importantly this will extend the patent protection by 20 years.